Expression and anticancer activity analysis of recombinant human uPA1‑43-melittin

Su,Manman; Chang,Weiqin; Cui,Manhua; Lin,Yang; Wu,Shuying; Xu,Tianmin

doi:10.3892/ijo.2014.2750

Expression and anticancer activity analysis of recombinant human uPA1‑43-melittin

Authors:
- Manman Su
- Weiqin Chang
- Manhua Cui
- Yang Lin
- Shuying Wu
- Tianmin Xu
View Affiliations

Affiliations: The Second Hospital, Jilin University, Changchun, P.R. China
Published online on: November 13, 2014 https://doi.org/10.3892/ijo.2014.2750
Pages: 619-626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study is focused on expression of a target fusion protein which can be used in ovarian cancer target therapy. It aimed to construct human urokinase-type plasminogen activator (uPA)1‑43-melittin eukaryotic expression vector to express recombinant human uPA1‑43-melittin (rhuPA1‑43-melittin) in P. pastoris and to detect its anticancer effects on ovarian cancer cells. The DNA sequences that encode uPA1‑43 amino acids and melittin were synthesized according to its native amino acid sequences and consequently inserted into pPICZαC vector. Then uPA1‑43-melittin -pPICZαC was transformed into P. pastoris X-33, and rhuPA1‑43-melittin was expressed by methonal inducing. The bioactivities of recombinant fusion protein were detected with inhibition effects on growth of ovarian cancer cells, cell cycle detection and TUNEL assay. The results of DNA sequence analysis of the recombinant vector uPA1‑43-melittin -pPICZαC demonstrated that the DNA encoding human uPA 1‑43 amino acids and 1-26 amino acids of melittin was correctly inserted into the pPICZαC vector. After being induced by methonal, fusion protein with molecular weight 7.6 kDa was observed on the basis of SDS-PAGE and western blot analysis. The recombinant protein was able to suppress growth of SKOV3, induce cell cycle arrest and apoptosis of SKOV3 cells. The fusion protein does not have any obvious toxicity on normal tissues. RhuPA1‑43-melittin was successfully expressed in P. pastoris. Taking uPA1‑43 amino acids specifically binding to uPAR as targeted part of fusion protein, and making use of antitumor activity of melittin, the recombinant fusion protein it was able to inhibit growth of ovarian tumors and to be applied for effective targeted treatment.

View Figures

View References

1	Thummarati P, Wijitburaphat S, Prasopthum A, Menakongka A, Sripa B, Tohtong R and Suthiphongchai T: High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol. 18:244–250. 2012. View Article : Google Scholar : PubMed/NCBI
2	Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I and Lee JH: Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res. 63:4648–4655. 2003.PubMed/NCBI
3	Blasi F and Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 3:932–943. 2002. View Article : Google Scholar : PubMed/NCBI
4	de Bock CE and Wang Y: Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 24:13–39. 2004. View Article : Google Scholar
5	Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 57:25–40. 2000. View Article : Google Scholar : PubMed/NCBI
6	Stepanova VV and Tkachuk VA: Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc). 67:109–118. 2002. View Article : Google Scholar
7	Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP and Andreasen PA: Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. Mol Cancer Res. 10:1532–1543. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR and Courtney M: A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. Eur J Biochem. 207:177–183. 1992. View Article : Google Scholar : PubMed/NCBI
9	Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J and Goltzman D: Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem. 267:14151–14156. 1992.PubMed/NCBI
10	Solberg H, Ploug M, Høyer-Hansen G, Nielsen BS and Lund LR: The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem. 49:237–246. 2001. View Article : Google Scholar : PubMed/NCBI
11	Li H, Ye X, Mahanivong C, Bian D, Chun J and Huang S: Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem. 280:10564–10571. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ljuca D, Fatusić Z, Iljazović E and Ahmetović B: Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn J Basic Med Sci. 7:111–116. 2007.PubMed/NCBI
13	Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C and Luther T: Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology. 57:461–471. 2010. View Article : Google Scholar : PubMed/NCBI
14	Ulisse S, Baldini E, Sorrenti S and D’Armiento M: The urokinase plasminogen activator system: a target for anticancer therapy. Curr Cancer Drug Targets. 9:32–71. 2009. View Article : Google Scholar : PubMed/NCBI
15	Shin JM, Jeong YJ, Cho HJ, Park KK, Chung IK, Lee IK, Kwak JY, Chang HW, Kim CH, Moon SK, Kim WJ, Choi YH and Chang YC: Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells. PLoS One. 8:e693802013. View Article : Google Scholar
16	Li B, Gu W, Zhang C, Huang XQ, Han KQ and Ling CQ: Growth arrest and apoptosis of the human hepatocellular carcinoma cell line BEL-7402 induced by melittin. Onkologie. 29:367–371. 2006. View Article : Google Scholar : PubMed/NCBI
17	Orsolić N, Sver L, Verstovsek S, Terzić S and Basić I: Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venom. Toxicon. 41:861–870. 2003. View Article : Google Scholar
18	Raghuraman H and Chattopadhyay A: Melittin: a membrane-active peptide with diverse functions. Biosci Rep. 27:189–223. 2007. View Article : Google Scholar
19	Tang J, Li J, Zeng G, Tang Y, Tian W, He J, York JP and Xia X: Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of in vitro cultured epithelial ovarian cancer cells. J Ovarian Res. 6:712013. View Article : Google Scholar : PubMed/NCBI
20	Gajski G and Garaj-Vrhovac V: Melittin: a lytic peptide with anticancer properties. Environ Toxicol Pharmacol. 36:697–705. 2013. View Article : Google Scholar : PubMed/NCBI
21	Gurkan C and Ellar DJ: Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact. 4:332005. View Article : Google Scholar : PubMed/NCBI